Value
8.1/10data confidence 67%| Component | Sub-score |
|---|---|
| P/E | 9.9 |
| P/S | 4.4 |
| EV/EBITDA | 5.6 |
| Analyst target | 9.0 |
- ▸Attractively valued
QTTB · Why this verdict
Why Q32 Bio (QTTB) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.9/10
ConfidenceMEDIUM
MacroNEUTRAL
Per-dimension breakdown
Quality
8.3/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 10.0 |
| ROA | 10.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 7.6 |
| FCF quality | 2.4 |
| Moat | 8.0 |
| Piotroski F | 6.7 |
- ▸Excellent ROE: 157%
- ▸Strong margins: 62%
- ▸Earnings quality RED FLAG: 30% FCF/NI
- ▸Wide economic moat
Growth
5.0/10data confidence 50%Momentum
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 8.5 |
| MACD | 0.7 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Oversold in uptrend (RSI 22)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
7.8/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 7.1 |
| Price target | 10.0 |
- ▸Light analyst coverage (4.0) — signal dampened
- ▸Analyst upside: 184%
Insider
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| materiality | 9.0 |
| insider conviction | 8.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Heavy insider buying — $30,000,000 (6.440% of mkt cap)
- ▸Institutions accumulating
Peer rank
6.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.6 |
| quality rank | 9.6 |
| growth rank | 5.0 |
- ▸Attractive P/E vs peers
- ▸Superior ROE vs peers
Technical
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 4.4 |
| support resistance | 6.2 |
| 52w position | 3.3 |
| gap | 5.0 |
Risk (lower is worse)
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.1 |
| days to cover | 10.0 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 7.0 |
| debt equity | 8.8 |
- ▸Short squeeze setup: 15% short, quality 7.5
- ▸Elevated put/call: 3.00
- ▸High IV: 115%
Catalyst
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| surprise avg | 10.0 |
| news activity | 7.0 |
- ▸Strong earnings: 3B/0M
How the verdict was assembled
Engine trigger
Value play: 63% MoS with quality 8.3. (held at prior verdict — engine reading is near the momentum/RSI threshold; will commit on clearer signal).
Engine technical detail
verdict_path:
L4:PATH_A_VALUE_MOS33|STABILIZER:PROMOTE_DEAD_ZONE|ENTRY_STICKY:PRIOR_STILL_VIABLEPassed (9)
- MOMENTUM:5.6>=5.5
- ASYMMETRY:9.4>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_BOOST:ANALYST_CLUSTER(3)
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
- SECTOR_CONCENTRATION_CAP:sector=Healthcare:3/10
Failed (0)
none
Warning (0)
none
Reward-to-Risk
9.42
Upside
+141.2%
Downside
15.0%
Sizing output
FULL
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.5B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The STRONG_BUY_WAIT verdict reflects clean gate clearance against Insider at 8.5 and asymmetric R:R of 9.42.
The strongest dimensions are Insider at 8.5, Quality at 8.3, and Value at 8.1; the weakest are Risk (lower is worse) at 4.7, Technical at 4.7, and Growth at 5.0. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 9.42 and an engine sizing output of FULL.